LadRx (CYTR) Stock Price, News & Analysis

Company Overview

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 4,000 shs
• Average Volume: 99,706 shs
• Market Capitalization: $4.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYTR Stock Analysis - Frequently Asked Questions

How were LadRx's earnings last quarter?

LadRx Co. (OTCMKTS:CYTR) announced its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02.

When did LadRx's stock split?

LadRx's stock reverse split on the morning of Wednesday, November 1st 2017.The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of LadRx?

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LadRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Biopharmx (BPMX), SELLAS Life Sciences Group (SLS), Rexahn Pharmaceuticals (REXN), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA) and Protalix BioTherapeutics (PLX).

Company Calendar

• Last Earnings: 8/09/2019
• Today: 7/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CYTR
• CIK: 799698
• Web: www.cytrx.com
• Phone: (310) 826-5648
• Fax: 310-826-6139
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.61%
• Return on Assets: -45.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.94
• Quick Ratio: 5.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 45,037,000
• Free Float: 33,834,000
• Market Cap: $4.14 million
• Optionable: Not Optionable
• Beta: 1.96